Fig. 6

Aberrant ATF5 amplification contributes to ATF5 overexpression in bladder cancer, which confers poor prognosis. A, B Analyses of ATF5 and DVL1 copy number variant (CNV) in bladder cancer patients from TCGA-BLCA data sets. C, D ATF5, DVL1 gene CNV and corresponding mRNA expression in bladder cancer patients from TCGA-BLCA data sets. E, F ATF5, DLV1 gene CNV and corresponding mRNA expression in a TCGA bladder cancer data set (P < 0.05). G ATF5 gene CNV and corresponding DVL1 gene expression in a TCGA bladder cancer data set (P = 0.939). H Kaplan–Meier analysis of relapse-free survival for patients with amplified, non-amplified or deletion of DVL1 expression (P = 0.379). I Kaplan–Meier analysis of relapse-free survival for patients with amplified, non-amplified or deletion of ATF5 expression (P = 0.014). *P < 0.05, **P < 0.01, ***P < 0.001. TCGA, the cancer genome atlas; BLCA, bladder urothelial carcinoma; CNV, copy number variant; Amp, amplification